Alnylam Pharmaceuticals reported $105.91M in Stock for its fiscal quarter ending in September of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Agios Pharmaceuticals USD 37.84M 2.09M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amgen USD 6.39B 169M Sep/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
BioCryst Pharmaceuticals USD 13.74M 7.68M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Incyte USD 134.25M 21.71M Sep/2026
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Moderna USD 313M 33M Sep/2026
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Novartis USD 6.1B 182M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Regeneron Pharmaceuticals USD 2.89B 189.7M Sep/2026
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
Takeda JPY 1.44T 6.17B Sep/2026
Ultragenyx Pharmaceutical USD 59M 0 Sep/2026
Vertex Pharmaceuticals USD 2.25B 480.2M Sep/2026